[1]
|
Kumar, S.K., Rajkumar, V., Kyle, R.A., van Duin, M., Sonneveld, P., Mateos, M.V., Gay, F. and Anderson, K.C. (2017) Multiple Myeloma. Nature Reviews Disease Primers, 3, Article No. 17046. https://doi.org/10.1038/nrdp.2017.46
|
[2]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[3]
|
Cowan, A.J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M.P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H.D., Jakovljevic, M., Khader, Y., Linn, S., Lad, D., Mantovani, L., Nong, V.M., Mokdad, A., Naghavi, M., Postma, M., Roshandel, G., Shackelford, K., Sisay, M., Nguyen, C.T., Tran, T.T., Xuan, B.T., Ukwaja, K.N., Vollset, S.E., Weiderpass, E., Libby, E.N. and Fitzmaurice, C.(2018) Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncology, 4, 1221-1227. https://doi.org/10.1001/jamaoncol.2018.2128
|
[4]
|
Rajkumar, S.V. and Kumar, S. (2016) Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings, 91, 101-119. https://doi.org/10.1016/j.mayocp.2015.11.007
|
[5]
|
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., LeLeu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., Jagannath, S., Sezer, O., Kristinsson, S.Y., Caers, J., Usmani, S.Z., Lahuerta, J.J..Johnsen, H.E., Beksac, M., Cavo, M., Goldschmidt, H., Terpos, E., Kyle, R.A., Anderson, K.C., Durie, B.G. and Miguel, J.F. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. https://doi.org/10.1016/S1470-2045(14)70442-5
|
[6]
|
Michels, T.C. and Petersen, K.E. (2017) Multiple Myeloma: Diagnosis and Treatment. American Family Physician, 95, 373-383.
|
[7]
|
Coleman, R.E., Croucher, P.I., Padhani, A.R., Clezardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R. and Costa, L. (2020) Bone Metastases. Nature Reviews Disease Primers, 6, Article No. 83. https://doi.org/10.1038/s41572-020-00216-3
|
[8]
|
Vallet, S., Filzmoser, J.M., Pecherstorfer, M. and Podar, K. (2018) Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics, 10, Article No. 202. https://doi.org/10.3390/pharmaceutics10040202
|
[9]
|
Rosen, C.J. (2000) The Epidemiology and Pathogenesis of Osteoporosis. Clinics in Laboratory Medicine, 20, 455-468. https://doi.org/10.1016/S0272-2712(18)30047-7
|
[10]
|
Zeng, Q., Li, N., Wang, Q., Feng, J., Sun, D., Zhang, Q., Huang, J., Wen, Q., Hu, R., Wang, L., Ma, Y., Fu, X., Dong, S. and Cheng, X. (2019) The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey. Journal of Bone and Mineral Research, 34, 1789-1797. https://doi.org/10.1002/jbmr.3757
|
[11]
|
Borgstrom, F., Karlsson, L., Ortsater, G., Norton, N., Halbout, P., Cooper, C., Lorentzon, M., McCloskey, E.V., Harvey, N.C., Javaid, M.K. and Kanis, J.A. (2020) Fragility Fractures in Europe: Burden, Management and Opportunities. Archives of Osteoporosis, 15, Article No. 59. https://doi.org/10.1007/s11657-020-0706-y
|
[12]
|
Dong, Z., Bonfil, R.D., Chinni, S., Deng, X., Trindade, F.J., Bernardo, M., Vaishampayan, U., Che, M., Sloane, B.F., Sheng, S., Fridman, R. and Cher, M. L. (2005) Matrix Metalloproteinase Activity and Osteoclasts in Experimental Prostate Cancer Bone Metastasis Tissue. The American Journal of Pathology, 166, 1173-1186. https://doi.org/10.1016/S0002-9440(10)62337-1
|
[13]
|
Henriksen, K., Bollerslev, J., Everts, V. and Karsdal, M. A. (2011) Osteoclast Activity and Subtypes as a Function of Physiology and Pathology—Implications for Future Treatments of Osteoporosis. Endocrine Reviews, 32, 31-63. https://doi.org/10.1210/er.2010-0006
|
[14]
|
Das, S. and Crockett, J.C. (2013) Osteoporosis—A Current View of Pharmacological Prevention and Treatment. Drug Design, Development and Therapy, 7, 435-448. https://doi.org/10.2147/DDDT.S31504
|
[15]
|
Teitelbaum, S.L. (2000) Bone Resorption by Osteoclasts. Science, 289, 1504-1508. https://doi.org/10.1126/science.289.5484.1504
|
[16]
|
Yokota, K., Sato, K., Miyazaki, T., Kitaura, H., Kayama, H., Miyoshi, F., Araki, Y., Akiyama, Y., Takeda, K. and Mimura, T. (2014) Combination of Tumor Necrosis Factor α and Interleukin-6 Induces Mouse Osteoclast-Like Cells with Bone Resorption Activity both in Vitro and in Vivo. Arthritis & Rheumatology, 66, 121-129. https://doi.org/10.1002/art.38218
|
[17]
|
Chau, J.F., Leong, W.F. and Li, B. (2009) Signaling Pathways Governing Osteoblast Proliferation, Differentiation and Function. Histology and Histopathology, 24, 1593-1606.
|
[18]
|
Meyer, M.B., Benkusky, N.A. and Pike, J.W. (2014) The RUNX2 Cistrome in Osteoblasts: Characterization, Down-Regulation Following Differentiation, and Relationship to Gene Expression. Journal of Biological Chemistry, 289, 16016-16031. https://doi.org/10.1074/jbc.M114.552216
|
[19]
|
Soltanoff, C.S., Yang, S., Chen, W. and Li, Y.-P. (2009) Signaling Networks that Control the Lineage Commitment and Differentiation of Bone Cells. Critical Reviews? in Eukaryotic Gene Expression, 19, 1-46. https://doi.org/10.1615/CritRevEukarGeneExpr.v19.i1.10
|
[20]
|
Linkhart, T.A., Mohan, S. and Baylink, D.J. (1996) Growth Factors for Bone Growth and Repair: IGF, TGFβ and BMP. Bone, 19, 1S-S12. https://doi.org/10.1016/S8756-3282(96)00138-X
|
[21]
|
Tan, S., Zhang, B., Zhu, X., Ao, P., Guo, H., Yi, W. and Zhou, G.-Q. (2014) Deregulation of Bone Forming Cells in Bone Diseases and Anabolic Effects of Strontium-Containing Agents and Biomaterials. BioMed Research International, 2014, Article ID: 814057. https://doi.org/10.1155/2014/814057
|
[22]
|
Marie, P.J. and Kassem, M. (2011) Osteoblasts in Osteoporosis: Past, Emerging, and Future Anabolic Targets. European Journal of Endocrinology, 165, 1-10. https://doi.org/10.1530/EJE-11-0132
|
[23]
|
Mao, B., Wu, W., Davidson, G., Marhold, J., Li, M., Mechler, B.M., Delius, H., Hoppe, D., Stannek, P., Walter, C., Glinka, A. and Niehrs, C. (2002) Kremen Proteins are Dickkopf Receptors That Regulate Wnt/β-Catenin Signalling. Nature, 417, 664-667. https://doi.org/10.1038/nature756
|
[24]
|
Bonewald, L.F. (2011) The Amazing Osteocyte. Journal of Bone and Mineral Research, 26, 229-238. https://doi.org/10.1002/jbmr.320
|
[25]
|
Dallas, S.L., Prideaux, M. and Bonewald, L.F. (2013) The Osteocyte: An Endocrine Cell... and More. Endocrine Reviews, 34, 658-690. https://doi.org/10.1210/er.2012-1026
|
[26]
|
Sims, N.A. and Walsh, N.C. (2012) Intercellular Cross-Talk among Bone Cells: New Factors and Pathways. Current Osteoporosis Reports, 10, 109-117. https://doi.org/10.1007/s11914-012-0096-1
|
[27]
|
Muruganandan, S., Ionescu, A.M. and Sinal, C.J. (2020) At the Crossroads of the Adipocyte and Osteoclast Differentiation Programs: Future Therapeutic Perspectives. International Journal of Molecular Sciences, 21, Article No. 2277. https://doi.org/10.3390/ijms21072277
|
[28]
|
Takeshita, S., Fumoto, T., Naoe, Y. and Ikeda, K. (2014) Age-Related Marrow Adipogenesis Is Linked to Increased Expression of RANKL. Journal of Biological Chemistry, 289, 16699-16710. https://doi.org/10.1074/jbc.M114.547919
|
[29]
|
Silbermann, R. and Roodman, G.D. (2013) Myeloma Bone Disease: Pathophysiology and Management. Journal of Bone Oncology, 2, 59-69. https://doi.org/10.1016/j.jbo.2013.04.001
|
[30]
|
Gau, Y.-C., Yeh, T.-J., Hsu, C.-M., Hsiao, S.-Y. and Hsiao, H.-H. (2022) Pathogenesis and Treatment of Myeloma-Related Bone Disease. International Journal of Molecular Sciences, 23, Article No. 3112. https://doi.org/10.3390/ijms23063112
|
[31]
|
Sezer, O., Heider, U., Zavrski, I., Kuhne, C.A. and Hofbauer, L.C. (2003) RANK Ligand and Osteoprotegerin in Myeloma Bone Disease. Blood, 101, 2094-2098. https://doi.org/10.1182/blood-2002-09-2684
|
[32]
|
Giuliani, N., Lisignoli, G., Colla, S., Lazzaretti, M., Storti, P., Mancini, C., Bonomini, S., Manferdini, C., Codeluppi, K., Facchini, A. and Rizzoli, V. (2008) CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3α and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions. Cancer Research, 68, 6840-6850. https://doi.org/10.1158/0008-5472.CAN-08-0402
|
[33]
|
Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, D.M., Martin, T.J., Hirota, H., Taga, T., Kishimoto, T. and Suda, T. (1995) Interleukin (IL)-6 Induction of Osteoclast Differentiation Depends on IL-6 Receptors Expressed on Osteoblastic Cells but Not on Osteoclast Progenitors. Journal of Experimental Medicine, 182, 1461-1468. https://doi.org/10.1084/jem.182.5.1461
|
[34]
|
Spaan, I., Raymakers, R.A., van de Stolpe, A. and Peperzak, V. (2018) Wnt Signaling in Multiple Myeloma: A Central Player in Disease with Therapeutic Potential. Journal of Hematology & Oncology, 11, Article No. 67. https://doi.org/10.1186/s13045-018-0615-3
|
[35]
|
Hideshima, T., Podar, K., Chauhan, D. and Anderson, K.C. (2005) Cytokines and Signal Transduction. Best Practice & Research Clinical Haematology, 18, 509-524. https://doi.org/10.1016/j.beha.2005.01.003
|
[36]
|
Gupta, D., Treon, S.P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.T., Lin, B., Lentzsch, S., Davies, F.E., Chauhan, D., Schlossman, R.L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D.I. and Anderson, K.C. (2001) Adherence of Multiple Myeloma Cells to Bone Marrow Stromal Cells Upregulates Vascular Endothelial Growth Factor Secretion: Therapeutic Applications. Leukemia, 15, 1950-1961. https://doi.org/10.1038/sj.leu.2402295
|
[37]
|
Giuliani, N., Storti, P., Bolzoni, M., Palma, B.D. and Bonomini, S. (2011) Angiogenesis and Multiple Myeloma. Cancer Microenvironment, 4, 325-337. https://doi.org/10.1007/s12307-011-0072-9
|
[38]
|
Terpos, E., Kastritis, E., Christoulas, D., Gkotzamanidou, M., Eleutherakis-Papaiakovou, E., Kanellias, N., Papatheodorou, A. and Dimopoulos, M.A. (2012) Circulating Activin-A Is Elevated in Patients with Advanced Multiple Myeloma and Correlates with Extensive Bone Involvement and Inferior Survival; No Alterations Post-Lenalidomide and Dexamethasone Therapy. Annals of Oncology, 23, 2681-2686. https://doi.org/10.1093/annonc/mds068
|
[39]
|
Podar, K., Chauhan, D. and Anderson, K.C. (2009) Bone Marrow Microenvironment and the Identification of New Targets for Myeloma Therapy. Leukemia, 23, 10-24. https://doi.org/10.1038/leu.2008.259
|
[40]
|
Michigami, T., Shimizu, N., Williams, P.J., Niewolna, M., Dallas, S.L., Mundy, G.R. and Yoneda, T. (2000) Cell–Cell Contact between Marrow Stromal Cells and Myeloma Cells via VCAM-1 and α4β1-Integrin Enhances Production of Osteoclast-Stimulating Activity. Blood, 96, 1953-1960. https://doi.org/10.1182/blood.V96.5.1953.h8001953_1953_1960
|
[41]
|
Joly, J.H., Lowry, W.E. and Graham, N.A. (2021) Differential Gene Set Enrichment Analysis: A Statistical Approach to Quantify the Relative Enrichment of Two Gene Sets. Bioinformatics, 36, 5247-5254. https://doi.org/10.1093/bioinformatics/btaa658
|
[42]
|
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S. and Mesirov, J.P. (2005) Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles. Proceedings of the National Academy of Sciences of the United States of America, 102, 15545-15550. https://doi.org/10.1073/pnas.0506580102
|
[43]
|
Yu, G., Wang, L.-G., Han, Y. and He, Q.-Y. (2012) ClusterProfiler: An R Package for Comparing Biological Themes among Gene Clusters. OMICS: A Journal of Integrative Biology, 16, 284-287. https://doi.org/10.1089/omi.2011.0118
|
[44]
|
Xiao, B., Liu, L., Li, A., Xiang, C., Wang, P., Li, H. and Xiao, T. (2020) Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma. Frontiers in Oncology, 10, Article 607622. https://doi.org/10.3389/fonc.2020.607622
|
[45]
|
Hanzelmann, S., Castelo, R. and Guinney, J. (2013) GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data. BMC Bioinformatics, 14, Article No. 7. https://doi.org/10.1186/1471-2105-14-7
|
[46]
|
Valderrabano, R.J. and Wu, J.Y. (2019) Bone and Blood Interactions in Human Health and Disease. Bone, 119, 65-70. https://doi.org/10.1016/j.bone.2018.02.019
|
[47]
|
During, A., Penel, G. and Hardouin, P. (2015) Understanding the Local Actions of Lipids in Bone Physiology. Progress in Lipid Research, 59, 126-146. https://doi.org/10.1016/j.plipres.2015.06.002
|
[48]
|
Chin, K.Y., Wong, S.K., Ekeuku, S.O. and Pang, K.L. (2020) Relationship between Metabolic Syndrome and Bone Health—An Evaluation of Epidemiological Studies and Mechanisms Involved. Diabetes, Metabolic Syndrome and Obesity, 13, 3667-3690. https://doi.org/10.2147/DMSO.S275560
|
[49]
|
Martyniak, K., Wei, F., Ballesteros, A., Meckmongkol, T., Calder, A., Gilbertson, T., Orlovskaya, N. and Coathup, M.J. (2021) Do Polyunsaturated Fatty Acids Protect against Bone Loss in Our Aging and Osteoporotic Population? Bone, 143, Article ID: 115736. https://doi.org/10.1016/j.bone.2020.115736
|
[50]
|
Su, Y., Elshorbagy, A., Turner, C., Refsum, H., Chan, R. and Kwok, T. (2019) Circulating Amino Acids Are Associated with Bone Mineral Density Decline and Ten-Year Major Osteoporotic Fracture Risk in Older Community-Dwelling Adults. Bone, 129, Article ID: 115082. https://doi.org/10.1016/j.bone.2019.115082
|
[51]
|
Karner, C.M. and Long, F. (2018) Glucose Metabolism in Bone. Bone, 115, 2-7. https://doi.org/10.1016/j.bone.2017.08.008
|
[52]
|
Arnett, T.R. and Orriss, I.R. (2018) Metabolic Properties of the Osteoclast. Bone, 115, 25-30. https://doi.org/10.1016/j.bone.2017.12.021
|
[53]
|
Da, W., Tao, L. and Zhu, Y. (2021) The Role of Osteoclast Energy Metabolism in the Occurrence and Development of Osteoporosis. Frontiers in Endocrinology, 12, Article 675385. https://doi.org/10.3389/fendo.2021.675385
|
[54]
|
Lee, W.-C., Guntur, A.R., Long, F. and Rosen, C.J. (2017) Energy Metabolism of the Osteoblast: Implications for Osteoporosis. Endocrine Reviews, 38, 255-266. https://doi.org/10.1210/er.2017-00064
|
[55]
|
Cheng, Y., Sun, F., Thornton, K., Jing, X., Dong, J., Yun, G., Pisano, M., Zhan, F., Kim, S.H., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Hari, P. and Janz, S. (2022) FOXM1 Regulates Glycolysis and Energy Production in Multiple Myeloma. Oncogene, 41, 3899-3911. https://doi.org/10.1038/s41388-022-02398-4
|
[56]
|
Xiang, Y., Fang, B., Liu, Y., Yan, S., Cao, D., Mei, H., Wang, Q., Hu, Y. and Guo, T. (2020) SR18292 Exerts Potent Antitumor Effects in Multiple Myeloma via Inhibition of Oxidative Phosphorylation. Life Sciences, 256, Article ID: 117971. https://doi.org/10.1016/j.lfs.2020.117971
|
[57]
|
Varrault, A., Ciani, E., Apiou, F., Bilanges, B., Hoffmann, A., Pantaloni, C., Bockaert, J., Spengler, D. and Journot, L. (1998) hZAC Encodes a Zinc Finger Protein with Antiproliferative Properties and Maps to a Chromosomal Region Frequently Lost in Cancer. Proceedings of the National Academy of Sciences of the United States of America, 95, 8835-8840. https://doi.org/10.1073/pnas.95.15.8835
|
[58]
|
Abdollahi, A. (2007) LOT1 (ZAC1/PLAGL1) and Its Family Members: Mechanisms and Functions. Journal of Cellular Physiology, 210, 16-25. https://doi.org/10.1002/jcp.20835
|
[59]
|
Vega-Benedetti, A.F., Saucedo, C., Zavattari, P., Vanni, R., Zugaza, J.L. and Parada, L.A. (2017) PLAGL1: An Important Player in Diverse Pathological Processes. Journal of Applied Genetics, 58, 71-78. https://doi.org/10.1007/s13353-016-0355-4
|
[60]
|
Cvetkovic, D., Pisarcik, D., Lee, C., Hamilton, T.C. and Abdollahi, A. (2004) Altered Expression and Loss of Heterozygosity of the LOT1 Gene in Ovarian Cancer. Gynecologic Oncology, 95, 449-455. https://doi.org/10.1016/j.ygyno.2004.08.051
|
[61]
|
Kowalczyk, A.E., Krazinski, B.E., Godlewski, J., Kiewisz, J., Kwiatkowski, P., Sliwinska-Jewsiewicka, A., Kiezun, J., Wierzbicki, P.M., Bodek, G., Sulik, M. and Kmiec, Z. (2015) Altered expression of the PLAGL1 (ZAC1/LOT1) Gene in Colorectal Cancer: Correlations to the Clinicopathological Parameters. International Journal of Oncology, 47, 951-962. https://doi.org/10.3892/ijo.2015.3067
|
[62]
|
Valleley, E.M.A., Cordery, S.F., Carr, I.M., MacLennan, K.A. and Bonthron, D.T. (2010) Loss of Expression of ZAC/PLAGL1 in Diffuse Large B-Cell Lymphoma Is Independent of Promoter Hypermethylation. Genes, Chromosomes and Cancer, 49, 480-486. https://doi.org/10.1002/gcc.20758
|
[63]
|
Wang, L., Huang, X., Chai, Y., Zou, L., Chedrawe, M. and Ding, Y. (2017) Octreotide Inhibits the Proliferation of Gastric Cancer Cells through P300-Hat Activity and the Interaction of ZAC and P300. Oncology Reports, 37, 2041-2048. https://doi.org/10.3892/or.2017.5451
|
[64]
|
Ribarska, T., Goering, W., Droop, J., Bastian, K.M., Ingenwerth, M. and Schulz, W.A. (2014) Deregulation of an Imprinted Gene Network in Prostate Cancer. Epigenetics, 9, 704-717. https://doi.org/10.4161/epi.28006
|
[65]
|
Su, H.-C., Wu, S.-C., Yen, L.-C., Chiao, L.-K., Wang, J.-K., Chiu, Y.-L., Ho, C.-L. and Huang, S.-M. (2020) Gene Expression Profiling Identifies the Role of Zac1 in Cervical Cancer Metastasis. Scientific Reports, 10, Article No. 11837. https://doi.org/10.1038/s41598-020-68835-0
|
[66]
|
Huang, S.-M., Schonthal, A.H. and Stallcup, M.R. (2001) Enhancement of p53-Dependent Gene Activation by the Transcriptional Coactivator Zac1. Oncogene, 20, 2134-2143. https://doi.org/10.1038/sj.onc.1204298
|
[67]
|
Liu, P.-Y., Hsieh, T.-Y., Liu, S.-T., Chang, Y.-L., Lin, W.-S., Wang, W.-M. and Huang, S.-M. (2011) Zac1, an Sp1-Like Protein, Regulates Human p21WAF1/Cip1 Gene Expression in HeLa Cells. Experimental Cell Research, 317, 2925-2937. https://doi.org/10.1016/j.yexcr.2011.09.018
|
[68]
|
DeBerardinis, R.J. (2020) Tumor Microenvironment, Metabolism, and Immunotherapy. New England Journal of Medicine, 382, 869-871. https://doi.org/10.1056/NEJMcibr1914890
|
[69]
|
Guillerey, C., Nakamura, K., Vuckovic, S., Hill, G.R. and Smyth, M.J. (2016) Immune Responses in Multiple Myeloma: Role of the Natural Immune Surveillance and Potential of Immunotherapies. Cellular and Molecular Life Sciences, 73, 1569-1589. https://doi.org/10.1007/s00018-016-2135-z
|
[70]
|
Brown, R.D., Spencer, A., Ho, P.J., Kennedy, N., Kabani, K., Yang, S., Sze, D.M., Aklilu, E., Gibson, J. and Joshua, D.E. (2009) Prognostically Significant Cytotoxic T Cell Clones Are Stimulated after Thalidomide Therapy in Patients with Multiple Myeloma. Leukemia & Lymphoma, 50, 1860-1864. https://doi.org/10.3109/10428190903216804
|
[71]
|
Du, D., Zhou, Z., Zhu, L., Hu, X., Lu, J., Shi, C., Chen, F. and Chen, A. (2018) TNF-α Suppresses Osteogenic Differentiation of MSCs by Accelerating P2Y2 Receptor in Estrogen-Deficiency Induced Osteoporosis. Bone, 117, 161-170. https://doi.org/10.1016/j.bone.2018.09.012
|
[72]
|
Liu, Z.Y. and Fu, R. (2021) Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients. Frontiers in Immunology, 12, Article 663748. https://doi.org/10.3389/fimmu.2021.663748
|
[73]
|
Favaloro, J., Liyadipitiya, T., Brown, R., Yang, S., Suen, H., Woodland, N., Nassif, N., Hart, D., Fromm, P., Weatherburn, C., Gibson, J., Ho, P.J. and Joshua, D. (2014) Myeloid Derived Suppressor Cells Are Numerically, Functionally and Phenotypically Different in Patients with Multiple Myeloma. Leukemia & Lymphoma, 55, 2893-2900. https://doi.org/10.3109/10428194.2014.904511
|
[74]
|
Gorgün, G.T., Whitehill, G., Anderson, J.L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N.C., Richardson, P.G. and Anderson, K.C. (2013) Tumor-Promoting Immune-Suppressive Myeloid-Derived Suppressor Cells in the Multiple Myeloma Microenvironment in Humans. Blood, 121, 2975-2987. https://doi.org/10.1182/blood-2012-08-448548
|
[75]
|
Wang, Z., Zhang, L., Wang, H., Xiong, S., Li, Y., Tao, Q., Xiao, W., Qin, H., Wang, Y. and Zhai, Z. (2015) Tumor-Induced CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells Correlate with Tumor Progression and Outcome of Therapy in Multiple Myeloma Patients. Cancer Immunology, Immunotherapy, 64, 389-399. https://doi.org/10.1007/s00262-014-1646-4
|
[76]
|
D’Arena, G., Rossi, G., Laurenti, L., Statuto, T., D’Auria, F., Valvano, L., Simeon, V., Giudice, A., Innocenti, I., De Feo, V., Filosa, R. and Musto, P. (2016) Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role. Journal of Immunology Research, 2016, Article ID: 9271469. https://doi.org/10.1155/2016/9271469
|
[77]
|
Kawano, Y., Roccaro, A.M., Ghobrial, I.M. and Azzi, J. (2017) Multiple Myeloma and the Immune Microenvironment. Current Cancer Drug Targets, 17, 806-818. https://doi.org/10.2174/1568009617666170214102301
|
[78]
|
Cline-Smith, A., Axelbaum, A., Shashkova, E., Chakraborty, M., Sanford, J., Panesar, P., Peterson, M., Cox, L., Baldan, A., Veis, D. and Aurora, R. (2020) Ovariectomy Activates Chronic Low-Grade Inflammation Mediated by Memory T Cells, Which Promotes Osteoporosis in Mice. Journal of Bone and Mineral Research, 35, 1174-1187. https://doi.org/10.1002/jbmr.3966
|
[79]
|
Soderstrom, K., Stein, E., Colmenero, P., Purath, U., Muller-Ladner, U., de Matos, C.T., Tarner, I.H., Robinson, W.H. and Engleman, E.G. (2010) Natural Killer Cells Trigger Osteoclastogenesis and Bone Destruction In Arthritis. Proceedings of the National Academy of Sciences of the United States of America, 107, 13028-13033. https://doi.org/10.1073/pnas.1000546107
|
[80]
|
Spengler, D., Villalba, M., Hoffmann, A., Pantaloni, C., Houssami, S., Bockaert, J. and Journot, L. (1997) Regulation of Apoptosis and Cell Cycle Arrest by Zac1, a Novel Zinc Finger Protein Expressed in the Pituitary Gland and the Brain. The EMBO Journal, 16, 2814-2825. https://doi.org/10.1093/emboj/16.10.2814
|
[81]
|
Abdollahi, A., Godwin, A.K., Miller, P.D., Getts, L.A., Schultz, D.C., Taguchi, T., Testa, J.R. and Hamilton, T.C. (1997) Identification of a Gene Containing Zinc-Finger Motifs Based on Lost Expression in Malignantly Transformed Rat Ovarian Surface Epithelial Cells. Cancer Research, 57, 2029-2034.
|
[82]
|
Abdollahi, A., Roberts, D., Godwin, A.K., Schultz, D.C., Sonoda, G., Testa, J.R. and Hamilton, T.C. (1997) Identification of a Zinc-Finger Gene at 6q25: A Chromosomal Region Implicated in Development of Many Solid Tumors. Oncogene, 14, 1973-1979. https://doi.org/10.1038/sj.onc.1201034
|
[83]
|
Kas, K., Voz, M.L., Hensen, K., Meyen, E. and Van de Ven, W.J. (1998) Transcriptional Activation Capacity of the Novel PLAG Family of Zinc Finger Proteins. Journal of Biological Chemistry, 273, 23026-23032. https://doi.org/10.1074/jbc.273.36.23026
|
[84]
|
Huang, S.-M. and Stallcup, M.R. (2000) Mouse Zac1, a Transcriptional Coactivator and Repressor for Nuclear Receptors. Molecular and Cellular Biology, 20, 1855-1867. https://doi.org/10.1128/MCB.20.5.1855-1867.2000
|
[85]
|
Varrault, A., Gueydan, C., Delalbre, A., Bellmann, A., Houssami, S., Aknin, C., Severac, D., Chotard, L., Kahli, M., Le Digarcher, A., Pavlidis, P. and Journot, L. (2006) Zac1 Regulates an Imprinted Gene Network Critically Involved in the Control of Embryonic Growth. Developmental Cell, 11, 711-722. https://doi.org/10.1016/j.devcel.2006.09.003
|